ABT, is repositioning its business after ongoing challenges in its Nutrition segment. The company is advancing a major acquisition of Exact Sciences to expand into oncology diagnostics. Management is ...

A new automation system from Abbott, designed to improve workflows in clinical lab settings, has been granted FDA approval. The system, GLP systems Track, uses a self-propelled carrier system that ...

The S&P 500 has performed well in 2023, but healthcare stocks have lagged behind. Abbott Laboratories continues to lap difficult comparable quarterly earnings reports, but the core business has been ...

Abbott posted strong organic growth of 11% in Q4 when excluding Covid testing sales. This year the stock will hit a milestone: 400 consecutive quarterly dividend payments. But consistency doesn't come ...

Abbott Laboratories reported strong Q4 2023 earnings, with year-over-year growth in EPS and revenue. The company's 2024 guidance projects further growth and improved ...

Abbott Laboratories (NYSE:ABT) received an FDA warning letter focused on the accuracy and testing of its FreeStyle Libre ...

On Wednesday, Abbott Laboratories (NYSE:ABT) reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus of $11.01 billion. Organic sales growth for the underlying ...